All In Biotech

Drug Trial Radar · NCT00430625

A Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Gaucher Disease

A Multicenter, Randomized, Double-Blind, Parallel Group, Two-Dose Study of Gene-Activated® Human Glucocerebrosidase (GA-GCB) Enzyme Replacement Therapy in Patients With Type 1 Gaucher Disease

Last checked: Nov 19, 2026Latest source record: Jun 29, 2021 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registryPivotal-lookingPhase 3. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

25

Actual

Start

Feb 15, 2007

Primary completion

Apr 1, 2009

Study completion Apr 1, 2009

Sponsor

Lead sponsor
ShireTakeda (TAK)
Sponsor type
Industry
First posted
Feb 2, 2007

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Double (participant, investigator)
Primary purpose
Treatment
Who can join
All sexes, from 2 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

Gaucher disease is a rare lysosomal storage disorder caused by the deficiency of the enzyme glucocerebrosidase (GCB). Due to this deficiency of functional GCB, glucocerebroside accumulates within macrophages leading to cellular engorgement, organomegaly, and organ system dysfunction. The purpose of this study is to evaluate the efficacy of every other week dosing of Gene-Activated® Human Glucocerebrosidase (GA-GCB, velaglucerase alfa) at doses of 45 and 60 U/kg in treatment-naïve patients with type 1 Gaucher disease.

Conditions

  • Gaucher Disease, Type 1

Interventions

  • VPRIV ®,Biological

    Intravenous (IV) infusion, every other week via intravenous infusion for 12 months

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Change From Baseline to 12 Months in Hemoglobin Concentration for the 60 U/kg Treatment Group.Time frame: Week 53

Locations

5 sites in 5 countries. Site status is shown where the registry gives one.

  • Hipolito Yrigoyen

    Buenos Aires, Argentina

  • Shaare Zedek Medical Center

    Jerusalem, Israel

  • Sociedad Espanola de Socorros Mutuos

    Asunción, Paraguay

  • National Research Center for Haematology

    Moscow, Russia

  • La Rabta Hospital

    Tunis, Tunisia

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.